{"name":"Shanghai Ark Biopharmaceutical Co., Ltd.","slug":"shanghai-ark-biopharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"AK0901 capsule","genericName":"AK0901 capsule","slug":"ak0901-capsule","indication":"Other","status":"phase_3"},{"name":"Ziresovir 125 mg","genericName":"Ziresovir 125 mg","slug":"ziresovir-125-mg","indication":"Other","status":"phase_1"},{"name":"AK0610 Injection solution","genericName":"AK0610 Injection solution","slug":"ak0610-injection-solution","indication":"Other","status":"phase_1"},{"name":"AK3280 Cream","genericName":"AK3280 Cream","slug":"ak3280-cream","indication":"Other","status":"phase_2"},{"name":"Matching placebo of AK0529","genericName":"Matching placebo of AK0529","slug":"matching-placebo-of-ak0529","indication":"Other","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AK0529","genericName":"AK0529","slug":"ak0529","indication":"FGFR-altered solid tumors (Phase 3 development)","status":"phase_3"}]}],"pipeline":[{"name":"AK0529","genericName":"AK0529","slug":"ak0529","phase":"phase_3","mechanism":"AK0529 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","indications":["FGFR-altered solid tumors (Phase 3 development)"],"catalyst":""},{"name":"AK0901 capsule","genericName":"AK0901 capsule","slug":"ak0901-capsule","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ziresovir 125 mg","genericName":"Ziresovir 125 mg","slug":"ziresovir-125-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK0610 Injection solution","genericName":"AK0610 Injection solution","slug":"ak0610-injection-solution","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK3280 Cream","genericName":"AK3280 Cream","slug":"ak3280-cream","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Matching placebo of AK0529","genericName":"Matching placebo of AK0529","slug":"matching-placebo-of-ak0529","phase":"phase_3","mechanism":"This is a placebo control formulation with no active pharmaceutical ingredient.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxOc2d6QzdyY3BWNUhFWk52WDMwREhSMmMwRUdIOGF6Y2tLeDdiRUp2T2xPSUdndy0xZjd2NUNFSFdwSUJmdW45NEFKTDZ0U2EtTDRBenpXSU5RS0p5aUNSVVJUTzQ4dW9OdEY5OFoxc1k3R3VhWmhLVXNhdFh6cnA3NDNQY0ZaSnozVUpsWmlhS1BTODgtMTYzd21SOG9xOVlWNWZPajJ0RHp3QXI5bnNlVkNnNS1WVERMU0tOLU1TczdSeS1aOGF6QVhTTnV3S2djMlZiT3ZuTmo0ZFNVXzhxUE83M1JSUHgybXNZYjVyVzV0d1RCRnhObzlB?oc=5","date":"2026-02-12","type":"regulatory","source":"PR Newswire","summary":"Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF - PR Newswire","headline":"Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNcW05NUVaV3NHTHRybVluOFJhOG1yRTdUM284bE83UlYteHRYdktjNkoyR1pMX0VWYlFZZXZqaVRSeGFGRTI2ZXljcDhhUlV6OFFodmFhaDlESjFQTHpPc3FPaXFVWWJTd2RLLTQ2bWptXzNvRGxyOEI4OWxTbm5TMWxWUzlNWDdYcThGbHlYMjJhY1VrNmlGN2J5cmg3eHI0RFlVT09XOC15NlRuSHBKUndZMEdNa3VTLWJ1bFRKWTBaeTE1Z0pBZjFZcjE2SkF5SUNkeHJrdkpuZnRRVGlvQkVEQ1BIcjkyeXc?oc=5","date":"2026-01-08","type":"pipeline","source":"PR Newswire","summary":"Ark Biopharmaceutical Receives China Marketing Authorization for Aizhida for the Treatment of ADHD - PR Newswire","headline":"Ark Biopharmaceutical Receives China Marketing Authorization for Aizhida for the Treatment of ADHD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxPOGpXb3NHVXBhYUpwOGthN1lCMGZqZjBNN0FKVWI5Wk5aMkVnT2x5UmtHNEI1M3dIMXoyWXNOSTlJekR1RVpWakpUYWhsYXVjT25yOXpyVmhPLTdLTGRxQ0ZRdmVMSW95cVJuTjdiXzY3Yk1BOGdVSmVtazZiX1FsckVzdVZxaTZpaFdBOXVzOFhFbTg4d19maWl6dENsS0ZZSjB6ejVMTldTVXUxdUk5eUQ1ZWNQOXdOZnpMN3B3X20yZXRxTjJtS25R?oc=5","date":"2025-07-16","type":"pipeline","source":"PR Newswire","summary":"ArkBio's Ziresovir Included into Pediatric RSV Drug Priority List by WHO - PR Newswire","headline":"ArkBio's Ziresovir Included into Pediatric RSV Drug Priority List by WHO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxQUW15ak1Odkk5bUxlb2cwYWUtSGFrbHl4OXoxUmdTRlJBcW91ZkJ5WDNGSGRmeHlxREFZa0VaZUZrZlB6S2ZhbGtZdEtXRGNHZGF1NmUtOWl2UmNKTE9kZDJMWEk4eGE0RkVJY0JILTl4Y2lsTVZzbEFRSUFYWXpvYUZqdnFiTmJORjhDQjZ2b01hcXA4VDlERTBZaDdpX29nUkJxRkpfWTVXaFR2WTVhOE1OdDZZU0tMU3RjU3pEdkJiTC05c0dYdzdMaFRoU21aWlVFYVRrRDBmX3ZpTGExQ0FNMXpNUGxkdkRTOG1uemk1ZGZ6R1N1bDdpTUxuN0E?oc=5","date":"2025-06-16","type":"pipeline","source":"PR Newswire","summary":"ArkBio's New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA - PR Newswire","headline":"ArkBio's New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxPSjgtLXQ1OF9MOFVLVTJqQm01ZjNCYm9qajJkT2lSTHBtWVdXc3QxVUVjVDR2RktPY3NWamZZekFHMGVtTURtOFBUT0dQSXdQRXR2OFFaeTRGUlJjV09zT0ZkdGZmY2pBMXlieHpJVmFJYkFxQVN6eFZwMUQ5eVQtUmo4U0o1aDVxTDc4cmVJT3RRV1MxT0hOM0V2VFV6ZWNHMXVRNU92V25NbGcwdTdJdHliMnlSZ2hPa05sNXprc1ZIOExJb1daRVJlV20yYVQ5dVEtLWoxalRPODVqQ3JEdmw1RmgwSk93ZzVPSmtsWkplWGdEcGxB?oc=5","date":"2025-05-16","type":"trial","source":"PR Newswire","summary":"ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF) - PR Newswire","headline":"ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxNRGM3bmZhRTFkdzdIck5NY2hrSEpzQ20wYy1wZURUOUkwTDRXWGRrYTJaRGZYdkJZRTBhdzh1eS1uWkxkMkdHU1VTbnBDQ2hVcnVIdVdqMTh3N0FIa0dRSnNXWHp2b1h6R0c1WEpjOGtMaTJIcGo3clFGUF95ZkJzbFBOOU5kRFpVM3cwLVA5c3J0Nl9HWHYzY0JBSmIwRUc1SEhtM2VBczNzTzVhQ3JobEJBU2tTUm9mVGZ3bWNrbllVdHhta0FmdDFRYjlvdnhoeUtONE54cldSc3ZfVDd5Y3ZXX3JsMy0yb3ItbENJT0FGNGxEa1RJTy0zbHpmMnlmSUZBUU1EOVBaSzZlaGxlWmZLVHpRYTltUTVqVU1INUR3a2daSTJrd1A0SXVaSW8?oc=5","date":"2025-03-24","type":"trial","source":"PR Newswire","summary":"ArkBio Announces the Completion of Phase III Clinical Study for AK0901 in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in China - PR Newswire","headline":"ArkBio Announces the Completion of Phase III Clinical Study for AK0901 in the Treatment of Attention Deficit Hyperactivi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgJBVV95cUxPc2JFcTZxMF9VZWo0WFFKSzRBemQ5S0ZfX2xaaEZPZ1hOMWEwZVlrdEtTUmV0ZVpjblpuU3dUZ3ZsVjNwb3FhRnhkOEdqZDl2XzRXUV9INTdvMlk1S25vcXcyZHktcVFydHczeWZaUmFzeFVJY1ljSHU3Sm9abF9VMFBFTEtncEVxTU96al9jLU94VWxPWVRRNEJpZDJnRlZENi1iSWpVZ3o4RUQ3cWdweGFRWFl3WWRPN2NCVjN5NmowbE1wTElRd2N6RFlUMEx5SmdheWNIVm1GSC1QWk5jbUgzbWFNeWJvSkJ4N1hHSVBQWXRzNVl4VmRJOFd2V0p2N3NtLW54TzMzbDhhRjNmRVNiUVdBR19lRTJTQ3RKeGdodjJNY3VOdEpzdnhMY0t4OUUtVmFzYmxyVzFVX0ZQbzRreU9XdzFwNF90LS1R?oc=5","date":"2024-11-25","type":"trial","source":"PR Newswire","summary":"ArkBio Announces Successful Completion of Enrollment and Dosing for Phase 1 Clinical Study of AK0610, a Preventive Antibody Against Respiratory Syncytial Virus Infection - PR Newswire","headline":"ArkBio Announces Successful Completion of Enrollment and Dosing for Phase 1 Clinical Study of AK0610, a Preventive Antib","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQaWJJZ1pfNVY1Z0phc1VsZFhlQmQxb21CWVBUai01VnhNZGQ3Y002T01VWEJMN3ZiaWZhMkQxN2YyQ19pVkdBVzA2UXNxZmt6VERaQ2lUTFZpNXc1STdzb0JTMzdJZ0pSWGk2ZkxaTnZhYzNtZEllaWRLbXlJamNQdkl5R3YtcU43c2JZWjNRdzZnYVgzT3JGRjBHTFdaS2U2YmZ4UllOc1dyUGxtRE5FWnUzLXhaV19nRUlFcWpaNUlwdw?oc=5","date":"2024-08-22","type":"pipeline","source":"BioPharma APAC","summary":"ArkBio CEO Presents Promising IPF Drug AK3280 at 8th Annual IPF Summit in Boston - BioPharma APAC","headline":"ArkBio CEO Presents Promising IPF Drug AK3280 at 8th Annual IPF Summit in Boston","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgJBVV95cUxNeVRNb1BiM01ncHcycWF5TVJZV2tjVzJ6QWl4RWpKd2JxTHVZeHhHUnNGdFBzdDlUaXhBUXE3UTlmTU9GUTNIcGhYS2dRVVdva0JtMGwxYnNieEo4cl9tNmJxeWlCQ0pjZkNDYmNETmhBX2RrSkpGM3pFUzVMX3k3YVVENWt5dk54ajkyUGYwVFppYTNpd2ZiSHNwY1dEMFQxRTVrTmhVNnU4RjlZSTJRdDNXV29FLVFBbThDRmFhUHMtV180U2RGX09EcUt1bndBR0R0Z0tCbzU5RlU0QXRxdXJYOGVROTF5a1VnbFJRazZzZGVvMHdhbUpMNFNGdm95ZllfY2VFSGZ0YmI0SXlQdFBBRXRrbkNCZ2daWFZJel9pR3ZxNDV2V2ZYajBwTHVsbW1FWHlEWkdNcmxmb0NSQnFuVldaQQ?oc=5","date":"2021-12-28","type":"deal","source":"globenewswire.com","summary":"Ark Biopharmaceutical Enters Into Exclusive License - globenewswire.com","headline":"Ark Biopharmaceutical Enters Into Exclusive License","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":3,"phase_1":2,"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}